Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-08-26 10:01 am Purchase | 13G | Eiger BioPharmaceuticals Inc. EIGR | Arkin Moshe | 149,371 10.090% | 96,300 (+181.46%) | View |
2024-07-01 06:47 am Sale | 13D | Eiger BioPharmaceuticals Inc. EIGR | Arkin Moshe | 53,071 3.580% | -4,428,055 (-98.82%) | View |
2024-04-08 09:28 am Purchase | 13D | Sol-Gel Technologies Ltd. SLGL | Arkin Moshe | 18,154,564 60.800% | 4,000,000 (+28.26%) | View |
2024-02-22 09:23 am Unchanged | 13D | UROGEN PHARMA LTD URGN | Arkin Moshe | 1,369,315 4.440% | 0 (Unchanged) | View |
2023-12-04 06:01 am Sale | 13D | Eiger BioPharmaceuticals Inc. EIGR | Arkin Moshe | 4,481,126 10.090% | -1,000 (-0.02%) | View |
2023-11-24 06:01 am Unchanged | 13D | Eiger BioPharmaceuticals Inc. EIGR | Arkin Moshe | 4,482,126 10.090% | 0 (Unchanged) | View |
2023-04-18 09:59 am Purchase | 13G | Eiger BioPharmaceuticals Inc. EIGR | Arkin Moshe | 4,482,126 10.150% | 1,769,124 (+65.21%) | View |
2023-03-20 4:45 pm Sale | 13D | Sol-Gel Technologies Ltd. SLGL | Arkin Moshe | 14,154,564 55.080% | -363,702 (-2.51%) | View |
2023-02-02 2:25 pm Purchase | 13G | Eiger BioPharmaceuticals Inc. EIGR | Arkin Moshe | 2,713,002 6.160% | 886,776 (+48.56%) | View |
2023-02-02 2:23 pm Sale | 13G | Keros Therapeutics Inc. KROS | Arkin Moshe | 1,371,074 4.980% | -441,241 (-24.35%) | View |
2023-02-02 2:15 pm Purchase | 13G | ONCORUS INC ONCR | Arkin Moshe | 2,508,481 9.660% | 1,041,392 (+70.98%) | View |
2022-04-12 06:18 am Unchanged | 13G | Keros Therapeutics Inc. KROS | Arkin Moshe | 1,812,315 7.550% | 0 (Unchanged) | View |
2022-04-11 4:57 pm Sale | 13G | Keros Therapeutics Inc. KROS | Arkin Moshe | 1,812,315 7.550% | -223,825 (-10.99%) | View |
2022-03-08 08:58 am Purchase | 13G | Eiger BioPharmaceuticals Inc. EIGR | Arkin Moshe | 1,826,226 5.380% | 1,826,226 (New Position) | View |
2021-12-02 4:15 pm Purchase | 13G | ONCORUS INC ONCR | Arkin Moshe | 1,467,089 5.680% | 1,467,089 (New Position) | View |
2021-05-10 11:21 am Purchase | 13D | WEREWOLF THERAPEUTICS INC HOWL | Arkin Moshe | 2,046,634 7.400% | 2,046,634 (New Position) | View |
2020-12-17 06:48 am Unchanged | 13D | Keros Therapeutics Inc. KROS | Arkin Moshe | 2,036,140 8.790% | 0 (Unchanged) | View |
2020-11-25 06:31 am Unchanged | 13D | Keros Therapeutics Inc. KROS | Arkin Moshe | 2,036,140 8.790% | 0 (Unchanged) | View |
2020-04-20 1:19 pm Purchase | 13D | Sol-Gel Technologies Ltd. SLGL | Arkin Moshe | 14,518,266 62.210% | 818,330 (+5.97%) | View |
2020-04-20 1:14 pm Purchase | 13D | Keros Therapeutics Inc. KROS | Arkin Moshe | 2,036,140 10.600% | 2,036,140 (New Position) | View |